237 related articles for article (PubMed ID: 16812953)
1. Prevention of iatrogenic transmission of B19 infection: different approaches to detect, remove or inactivate virus contamination.
Bonvicini F; Gallinella G; Gentilomi GA; Ambretti S; Musiani M; Zerbini M
Clin Lab; 2006; 52(5-6):263-8. PubMed ID: 16812953
[TBL] [Abstract][Full Text] [Related]
2. Safety issues for plasma derivatives and benefit from NAT testing.
Willkommen H; Schmidt I; Löwer J
Biologicals; 1999 Dec; 27(4):325-31. PubMed ID: 10686059
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of different assays for the detection of parvovirus B19 DNA in human plasma.
Baylis SA; Shah N; Minor PD
J Virol Methods; 2004 Oct; 121(1):7-16. PubMed ID: 15350727
[TBL] [Abstract][Full Text] [Related]
4. Molecular testing for detection of in vitro infectivity of plasma pools contaminated with B19 virus.
Bonvicini F; Gallinella G; Cricca M; Ambretti S; Delbarba S; Musiani M; Zerbini M
J Med Virol; 2004 Oct; 74(2):272-6. PubMed ID: 15332276
[TBL] [Abstract][Full Text] [Related]
5. Inactivation of parvovirus B19 by liquid heating incorporated in the manufacturing process of human intravenous immunoglobulin preparations.
Yunoki M; Urayama T; Tsujikawa M; Sasaki Y; Abe S; Takechi K; Ikuta K
Br J Haematol; 2005 Feb; 128(3):401-4. PubMed ID: 15667545
[TBL] [Abstract][Full Text] [Related]
6. Reducing the risk of infection from plasma products: specific preventative strategies.
Burnouf T; Radosevich M
Blood Rev; 2000 Jun; 14(2):94-110. PubMed ID: 11012252
[TBL] [Abstract][Full Text] [Related]
7. Effect of viral nucleic acid testing on contamination frequency of manufacturing plasma pools.
Nübling CM; Unkelbach U; Chudy M; Seitz R
Transfusion; 2008 May; 48(5):822-6. PubMed ID: 18208414
[TBL] [Abstract][Full Text] [Related]
8. Variability of parvovirus B19 to inactivation by liquid heating in plasma products.
Hattori S; Yunoki M; Tsujikawa M; Urayama T; Tachibana Y; Yamamoto I; Yamamoto S; Ikuta K
Vox Sang; 2007 Feb; 92(2):121-4. PubMed ID: 17298573
[TBL] [Abstract][Full Text] [Related]
9. [Detection of B19 parvovirus in plasma pools before solvent-detergent treatment of plasma: AFSSAPS and EFS Aquitaine-Limousin's experience].
Petermann R; Piquet Y; Lapeyre M; Goujon N; Gauthier M; Lalanne V; Mouillot L; Tissier MH; Boiron JM
Transfus Clin Biol; 2010 Apr; 17(2):54-62. PubMed ID: 20674438
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of nucleic acid sequences specific for human parvoviruses, hepatitis A and hepatitis E viruses in coagulation factor concentrates.
Modrow S; Wenzel JJ; Schimanski S; Schwarzbeck J; Rothe U; Oldenburg J; Jilg W; Eis-Hübinger AM
Vox Sang; 2011 May; 100(4):351-8. PubMed ID: 21133933
[TBL] [Abstract][Full Text] [Related]
11. Prevalence and quantitation of parvovirus B19 DNA levels in blood donors with a sensitive polymerase chain reaction screening assay.
Kleinman SH; Glynn SA; Lee TH; Tobler L; Montalvo L; Todd D; Kiss JE; Shyamala V; Busch MP;
Transfusion; 2007 Oct; 47(10):1756-64. PubMed ID: 17880600
[TBL] [Abstract][Full Text] [Related]
12. Parvovirus B19 DNA in Factor VIII concentrates: effects of manufacturing procedures and B19 screening by nucleic acid testing.
Geng Y; Wu CG; Bhattacharyya SP; Tan D; Guo ZP; Yu MY
Transfusion; 2007 May; 47(5):883-9. PubMed ID: 17465954
[TBL] [Abstract][Full Text] [Related]
13. [Safety of blood products and B19 parvovirus].
Lefrère JJ; Maniez-Montreuil M; Morel P; Defer C; Laperche S
Transfus Clin Biol; 2006 Oct; 13(4):235-41. PubMed ID: 16822687
[TBL] [Abstract][Full Text] [Related]
14. Variants of B19.
Brown KE
Dev Biol (Basel); 2004; 118():71-7. PubMed ID: 15645675
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of a new LightCycler reverse transcription-polymerase chain reaction infectivity assay for detection of human parvovirus B19 in dry-heat inactivation studies.
Prikhod'ko GG; Vasilyeva I; Reyes H; Wong S; Brown KE; Jameson T; Busby TF
Transfusion; 2005 Jun; 45(6):1011-9. PubMed ID: 15935001
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of Parvovirus B19 and Hepatitis A virus in Portuguese blood donors.
Henriques I; Monteiro F; Meireles E; Cruz A; Tavares G; Ferreira M; Araújo F
Transfus Apher Sci; 2005 Nov; 33(3):305-9. PubMed ID: 16203176
[TBL] [Abstract][Full Text] [Related]
17. Parvovirus B19 transmission by a high-purity factor VIII concentrate.
Wu CG; Mason B; Jong J; Erdman D; McKernan L; Oakley M; Soucie M; Evatt B; Yu MY
Transfusion; 2005 Jun; 45(6):1003-10. PubMed ID: 15935000
[TBL] [Abstract][Full Text] [Related]
18. [Viral safety in hemotherapy. Current aspects of hepatitis C and parvovirus B19 detection for plasma component therapy].
Sibrowski W; Kühnl P
Beitr Infusionsther; 1990; 26():22-6. PubMed ID: 1703836
[TBL] [Abstract][Full Text] [Related]
19. Human erythrovirus B19 and blood transfusion - an update.
Parsyan A; Candotti D
Transfus Med; 2007 Aug; 17(4):263-78. PubMed ID: 17680952
[TBL] [Abstract][Full Text] [Related]
20. Viral safety of Nanogam, a new 15 nm-filtered liquid immunoglobulin product.
Terpstra FG; Parkkinen J; Tölö H; Koenderman AH; Ter Hart HG; von Bonsdorff L; Törmä E; van Engelenburg FA
Vox Sang; 2006 Jan; 90(1):21-32. PubMed ID: 16359352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]